[Retrospectively analysis of characteristics and risk factors of immune treatment-related hepatic adverse events in malignant tumor].

Objective: To explore the clinical features and risk factors of hepatic injury due to immune checkpoint inhibitors (CPI) therapy in malignant tumor. Methods: Data of 112 patients (64 men and 48 women) who received CPI between January 2016 and March 2019 in Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen Hospital, and Huazhong University of Science and Techology Union Shenzhen Hospital were retrospectively collected. The median age of these patients was 60 years. Results: Hepatic adverse events were observed in 30 patients out of 112 patients (26.8%). Among them, the incidence of grade 3-5 hepatic adverse events were 7.14% (8/112). The median time of hepatic adverse event occurrence was 3 weeks (2-30) after undergoing therapy. The results of univariate and multivariate analyses showed that liver cancer was attributed to the CPI induced hepatitis (P<0.05). Patients with severe hepatic injury got almost complete resolution after receiving methlprednisolone for 4 to 6 weeks. Conclusion: Live cancer is the risk factor of CPI-related hepatic adverse events.目的： 探讨恶性肿瘤患者免疫治疗相关肝毒性的临床特征及其影响因素。 方法： 回顾性分析2016年1月至2019年3月就诊于中国医学科学院肿瘤医院深圳医院南山肿瘤中心和华中科技大学协和深圳医院接受免疫检查点抑制剂治疗的112例恶性肿瘤患者的临床资料，其中男64例，女48例；中位年龄60岁。 结果： 112例患者中，肝不良事件发生率为26.8%(30/112)，3～5级肝不良事件发生率为7.14%(8/112)，出现肝不良事件的中位时间为接受免疫治疗后3周。单因素及多因素分析均显示，患者肝不良事件的发生与肝癌有关(P<0.05)。发生3～5级肝不良事件患者接受规范甲强龙治疗后，4～6周内肝功能恢复。 结论： 肝癌为恶性肿瘤患者免疫治疗发生相关肝脏不良事件的危险因素。.